- Pfizer Inc.
- Novartis AG
- Elan Corp. PLC
- CoTherix Inc.
- Schering AG
- Genzyme Corp.
- Bioenvision Inc.
- Ilex Oncology Inc.
- Fougera Pharmaceuticals Inc.
- Genentech Inc.
- OSI Pharmaceuticals LLC
- Eli Lilly & Co.
- Boehringer Ingelheim International GmbH
- Neurex Corp.
- Astellas Pharma Inc.
- GlaxoSmithKline PLC
- Novartis buys Pfizer's Enablex for CHF310.5mm
- CoTherix licenses rights to Ventavis from Schering AG
- Bioenvision and Ilex to co-develop clofarabine
- Aventis co-promotes Byk Gulden's Ciclesonide in US
- Genentech and Roche license OSI's lead drug
- Lilly, Boehringer Ingelheim in duloxetine co-promotion
- Elan acquires Neurex Corp. for $741mm in stock swap
- Boehringer Ingelheim, Pfizer to co-promote Spiriva
- GlaxoSmithKline to sell Yamanouchi's Vesicare in US
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.